Resolution and Prevention of Feline Immunodeficiency Virus-Induced Neurological Deficits by Treatment with the Protease Inhibitor TL-3

Salvador Huitron-Resendiz, Sohela De Rozières, Manuel Sanchez-Alavez, Bernd Bühler, Ying Chuan Lin, Danica L. Lerner, Nicholas W. Henriksen, Mboya Burudi, Howard S. Fox, Bruce E. Torbett, Steven Henriksen, John H. Elder

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

In vivo tests were performed to assess the influence of the protease inhibitor TL-3 on feline immunodeficiency virus (FIV)-induced central nervous system (CNS) deficits. Twenty cats were divided into four groups of five animals each. Group 1 received no treatment, group 2 received TL-3 only, group 3 received FIV strain PPR (FIV-PPR) only, and group 4 received FIV-PPR and TL-3. Animals were monitored for immunological and virological status, along with measurements of brain stem auditory evoked potential (BAEP) changes. Groups 1 and 2 remained FIV negative, and groups 3 and 4 became virus positive and seroconverted by 3 to 5 weeks postinoculation. No adverse effects were noted with TL-3 only. The average peak viral load for the virus-only group 3 animals was 1.32 × 106 RNA copies/ml, compared to 6.9 × 10 4 copies/ml for TL-3-treated group 4 cats. Group 3 (virus-only) cats exhibited marked progressive delays in BAEPs starting at 2 weeks post virus exposure, which is typical of infection with FIV-PPR. In contrast, TL-3-treated cats of group 4 exhibited BAEPs similar to those of control and drug-only cats. At 97 days postinfection, treatments were switched; i.e., group 4 animals were taken off TL-3 and group 3 animals were treated with TL-3. BAEPs in group 3 animals returned to control levels, while BAEPs in group 4 animals remained at control levels. After 70 days on TL-3, group 3 was removed from the drug treatment regimen. Delays in BAEPs immediately increased to levels observed prior to TL-3 treatment. The findings show that early TL-3 treatment can effectively eliminate FIV-induced changes in the CNS. Furthermore, TL-3 can counteract FIV effects on the CNS of infected cats, although continued treatment is required to maintain unimpaired CNS function.

Original languageEnglish (US)
Pages (from-to)4525-4532
Number of pages8
JournalJournal of virology
Volume78
Issue number9
DOIs
StatePublished - May 1 2004

Fingerprint

Feline Immunodeficiency Virus
Feline immunodeficiency virus
proteinase inhibitors
Protease Inhibitors
Cats
cats
central nervous system
Central Nervous System
animals
Viruses
viruses
evoked potentials
Brain Stem Auditory Evoked Potentials
Drug and Narcotic Control
brain stem
viral load
Viral Load
drug therapy
adverse effects
RNA

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Insect Science
  • Virology

Cite this

Huitron-Resendiz, S., De Rozières, S., Sanchez-Alavez, M., Bühler, B., Lin, Y. C., Lerner, D. L., ... Elder, J. H. (2004). Resolution and Prevention of Feline Immunodeficiency Virus-Induced Neurological Deficits by Treatment with the Protease Inhibitor TL-3. Journal of virology, 78(9), 4525-4532. https://doi.org/10.1128/JVI.78.9.4525-4532.2004

Resolution and Prevention of Feline Immunodeficiency Virus-Induced Neurological Deficits by Treatment with the Protease Inhibitor TL-3. / Huitron-Resendiz, Salvador; De Rozières, Sohela; Sanchez-Alavez, Manuel; Bühler, Bernd; Lin, Ying Chuan; Lerner, Danica L.; Henriksen, Nicholas W.; Burudi, Mboya; Fox, Howard S.; Torbett, Bruce E.; Henriksen, Steven; Elder, John H.

In: Journal of virology, Vol. 78, No. 9, 01.05.2004, p. 4525-4532.

Research output: Contribution to journalArticle

Huitron-Resendiz, S, De Rozières, S, Sanchez-Alavez, M, Bühler, B, Lin, YC, Lerner, DL, Henriksen, NW, Burudi, M, Fox, HS, Torbett, BE, Henriksen, S & Elder, JH 2004, 'Resolution and Prevention of Feline Immunodeficiency Virus-Induced Neurological Deficits by Treatment with the Protease Inhibitor TL-3', Journal of virology, vol. 78, no. 9, pp. 4525-4532. https://doi.org/10.1128/JVI.78.9.4525-4532.2004
Huitron-Resendiz, Salvador ; De Rozières, Sohela ; Sanchez-Alavez, Manuel ; Bühler, Bernd ; Lin, Ying Chuan ; Lerner, Danica L. ; Henriksen, Nicholas W. ; Burudi, Mboya ; Fox, Howard S. ; Torbett, Bruce E. ; Henriksen, Steven ; Elder, John H. / Resolution and Prevention of Feline Immunodeficiency Virus-Induced Neurological Deficits by Treatment with the Protease Inhibitor TL-3. In: Journal of virology. 2004 ; Vol. 78, No. 9. pp. 4525-4532.
@article{4585543bde8647a4b02ebb4b81cb20d8,
title = "Resolution and Prevention of Feline Immunodeficiency Virus-Induced Neurological Deficits by Treatment with the Protease Inhibitor TL-3",
abstract = "In vivo tests were performed to assess the influence of the protease inhibitor TL-3 on feline immunodeficiency virus (FIV)-induced central nervous system (CNS) deficits. Twenty cats were divided into four groups of five animals each. Group 1 received no treatment, group 2 received TL-3 only, group 3 received FIV strain PPR (FIV-PPR) only, and group 4 received FIV-PPR and TL-3. Animals were monitored for immunological and virological status, along with measurements of brain stem auditory evoked potential (BAEP) changes. Groups 1 and 2 remained FIV negative, and groups 3 and 4 became virus positive and seroconverted by 3 to 5 weeks postinoculation. No adverse effects were noted with TL-3 only. The average peak viral load for the virus-only group 3 animals was 1.32 × 106 RNA copies/ml, compared to 6.9 × 10 4 copies/ml for TL-3-treated group 4 cats. Group 3 (virus-only) cats exhibited marked progressive delays in BAEPs starting at 2 weeks post virus exposure, which is typical of infection with FIV-PPR. In contrast, TL-3-treated cats of group 4 exhibited BAEPs similar to those of control and drug-only cats. At 97 days postinfection, treatments were switched; i.e., group 4 animals were taken off TL-3 and group 3 animals were treated with TL-3. BAEPs in group 3 animals returned to control levels, while BAEPs in group 4 animals remained at control levels. After 70 days on TL-3, group 3 was removed from the drug treatment regimen. Delays in BAEPs immediately increased to levels observed prior to TL-3 treatment. The findings show that early TL-3 treatment can effectively eliminate FIV-induced changes in the CNS. Furthermore, TL-3 can counteract FIV effects on the CNS of infected cats, although continued treatment is required to maintain unimpaired CNS function.",
author = "Salvador Huitron-Resendiz and {De Rozi{\`e}res}, Sohela and Manuel Sanchez-Alavez and Bernd B{\"u}hler and Lin, {Ying Chuan} and Lerner, {Danica L.} and Henriksen, {Nicholas W.} and Mboya Burudi and Fox, {Howard S.} and Torbett, {Bruce E.} and Steven Henriksen and Elder, {John H.}",
year = "2004",
month = "5",
day = "1",
doi = "10.1128/JVI.78.9.4525-4532.2004",
language = "English (US)",
volume = "78",
pages = "4525--4532",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "9",

}

TY - JOUR

T1 - Resolution and Prevention of Feline Immunodeficiency Virus-Induced Neurological Deficits by Treatment with the Protease Inhibitor TL-3

AU - Huitron-Resendiz, Salvador

AU - De Rozières, Sohela

AU - Sanchez-Alavez, Manuel

AU - Bühler, Bernd

AU - Lin, Ying Chuan

AU - Lerner, Danica L.

AU - Henriksen, Nicholas W.

AU - Burudi, Mboya

AU - Fox, Howard S.

AU - Torbett, Bruce E.

AU - Henriksen, Steven

AU - Elder, John H.

PY - 2004/5/1

Y1 - 2004/5/1

N2 - In vivo tests were performed to assess the influence of the protease inhibitor TL-3 on feline immunodeficiency virus (FIV)-induced central nervous system (CNS) deficits. Twenty cats were divided into four groups of five animals each. Group 1 received no treatment, group 2 received TL-3 only, group 3 received FIV strain PPR (FIV-PPR) only, and group 4 received FIV-PPR and TL-3. Animals were monitored for immunological and virological status, along with measurements of brain stem auditory evoked potential (BAEP) changes. Groups 1 and 2 remained FIV negative, and groups 3 and 4 became virus positive and seroconverted by 3 to 5 weeks postinoculation. No adverse effects were noted with TL-3 only. The average peak viral load for the virus-only group 3 animals was 1.32 × 106 RNA copies/ml, compared to 6.9 × 10 4 copies/ml for TL-3-treated group 4 cats. Group 3 (virus-only) cats exhibited marked progressive delays in BAEPs starting at 2 weeks post virus exposure, which is typical of infection with FIV-PPR. In contrast, TL-3-treated cats of group 4 exhibited BAEPs similar to those of control and drug-only cats. At 97 days postinfection, treatments were switched; i.e., group 4 animals were taken off TL-3 and group 3 animals were treated with TL-3. BAEPs in group 3 animals returned to control levels, while BAEPs in group 4 animals remained at control levels. After 70 days on TL-3, group 3 was removed from the drug treatment regimen. Delays in BAEPs immediately increased to levels observed prior to TL-3 treatment. The findings show that early TL-3 treatment can effectively eliminate FIV-induced changes in the CNS. Furthermore, TL-3 can counteract FIV effects on the CNS of infected cats, although continued treatment is required to maintain unimpaired CNS function.

AB - In vivo tests were performed to assess the influence of the protease inhibitor TL-3 on feline immunodeficiency virus (FIV)-induced central nervous system (CNS) deficits. Twenty cats were divided into four groups of five animals each. Group 1 received no treatment, group 2 received TL-3 only, group 3 received FIV strain PPR (FIV-PPR) only, and group 4 received FIV-PPR and TL-3. Animals were monitored for immunological and virological status, along with measurements of brain stem auditory evoked potential (BAEP) changes. Groups 1 and 2 remained FIV negative, and groups 3 and 4 became virus positive and seroconverted by 3 to 5 weeks postinoculation. No adverse effects were noted with TL-3 only. The average peak viral load for the virus-only group 3 animals was 1.32 × 106 RNA copies/ml, compared to 6.9 × 10 4 copies/ml for TL-3-treated group 4 cats. Group 3 (virus-only) cats exhibited marked progressive delays in BAEPs starting at 2 weeks post virus exposure, which is typical of infection with FIV-PPR. In contrast, TL-3-treated cats of group 4 exhibited BAEPs similar to those of control and drug-only cats. At 97 days postinfection, treatments were switched; i.e., group 4 animals were taken off TL-3 and group 3 animals were treated with TL-3. BAEPs in group 3 animals returned to control levels, while BAEPs in group 4 animals remained at control levels. After 70 days on TL-3, group 3 was removed from the drug treatment regimen. Delays in BAEPs immediately increased to levels observed prior to TL-3 treatment. The findings show that early TL-3 treatment can effectively eliminate FIV-induced changes in the CNS. Furthermore, TL-3 can counteract FIV effects on the CNS of infected cats, although continued treatment is required to maintain unimpaired CNS function.

UR - http://www.scopus.com/inward/record.url?scp=16544368098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16544368098&partnerID=8YFLogxK

U2 - 10.1128/JVI.78.9.4525-4532.2004

DO - 10.1128/JVI.78.9.4525-4532.2004

M3 - Article

C2 - 15078933

AN - SCOPUS:16544368098

VL - 78

SP - 4525

EP - 4532

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 9

ER -